Patents by Inventor Sanjay Malhotra
Sanjay Malhotra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11892401Abstract: The present disclosure relates to novel boronic acid receptor compounds and their use in methods of quantifying a saccharide appearing in a sample. Provided are methods of measuring the concentration of a saccharide in a sample as well as methods of measuring the concentration of a halogenated saccharide in a sample. In certain aspects the sample is abiological sample and the methods further include correlating the measured concentration of saccharide in the biological sample to the gastrointestinal permeability in the individual. Disclosed are also kits for performing the above methods.Type: GrantFiled: February 12, 2019Date of Patent: February 6, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Angel Resendez, Sanjay Malhotra
-
Publication number: 20230382862Abstract: The present disclosure relates generally to compounds suitable as ERG inhibitors, including compositions comprising such compounds, methods for their use in treating diseases associated with overexpression of wild type ERG protein, an altered ERG protein, ERG gene transcription or ERG mRNA translation, and methods of making such compounds.Type: ApplicationFiled: June 18, 2021Publication date: November 30, 2023Inventors: Albert L. Dobi, Sanjay Malhotra, Mallesh Pandrala
-
Patent number: 11771692Abstract: Compounds, compositions and methods are provided for the inhibition of GBP1. The subject inhibitor compounds can act by inhibiting GBP1 alone and/or GBP1: pro-survival kinase (e.g. serine/threonine-protein kinase pim-1 (PIM1)) interactions. Aspects of the subject methods include contacting a cellular sample with a GBP 1 inhibitor to inhibit the GBP 1 alone and/or GBP 1: PIM 1 interactions. Also provided are compositions and methods for treating cancer. In certain cases the cancer is resistant towards chemotherapy and radiation therapy.Type: GrantFiled: March 12, 2019Date of Patent: October 3, 2023Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sanjay Malhotra, Vineet Kumar, Dhanir Tailor
-
Patent number: 11730705Abstract: ?-NETA analogs are provided for the treatment of inflammatory disease.Type: GrantFiled: April 13, 2020Date of Patent: August 22, 2023Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States Government As Represented By The Department of Veterans AffairsInventors: Sanjay Malhotra, Vineet Kumar, Melissa LaJevic, Mallesh Pandrala, Brian A. Zabel
-
Publication number: 20230047251Abstract: Provided are methods for treating neuropathic pain by administering to a subject in need thereof a compound comprising phenyl-indole scaffold, wherein the compound has a modulatory effect on cannabinoid type 1 receptor (CB1R). Pharmaceutical compositions containing compounds comprising phenyl-indole scaffolds and pharmaceutically acceptable carriers are also provided, along with methods of using the same.Type: ApplicationFiled: February 3, 2021Publication date: February 16, 2023Inventors: Sanjay Malhotra, Brian K. Kobilka, Kaavya Krishna Kumar, Angel Resendez
-
Publication number: 20230003715Abstract: Methods of inhibiting the proliferation of a cancer cell, and treating cancer in an individual are provided. Aspects of the subject methods include contacting a cancer cell with an azapodophyllotoxin derivative, where the contacting is effective to inhibit tubulin polymerization and monoglycerol metabolism to inhibit proliferation of cancer in the cell. In certain cases, the cancer cell is a renal cancer cell (RCC) or a lymphoma cell. Aspects of the methods also include administering to a subject an effective amount of an azapodophyllotoxin derivative to treat the subject for cancer, where the cancer is selected from renal cancer and lymphoma. Also provided is a method of monitoring tumor regression in an individual, and methods of identifying a cancer suppressing compound.Type: ApplicationFiled: November 3, 2020Publication date: January 5, 2023Inventors: Arvin Gouw, Sanjay Malhotra, Dean W. Felsher
-
Publication number: 20210393628Abstract: This invention is in the field of medicinal chemistry. In particular, provided herein are compositions and methods for preventing or reversing T cell exhaustion. In certain embodiments, the present invention relates to methods of preventing or reversing T cell exhaustion by exposing T cells experiencing T cell exhaustion to a new class of small-molecules having a thiazole, imidazolepyridiazine or piperazinyl-methyl-aniline structure, or by expanding genetically engineered T cells in the presence of such small molecules.Type: ApplicationFiled: October 30, 2019Publication date: December 23, 2021Inventors: Crystal Mackall, Vineet Kumar, Mallesh Pandrala, Evan Weber, Sanjay Malhotra
-
Publication number: 20210364437Abstract: The present disclosure relates to novel boronic acid receptor compounds and their use in methods of quantifying a saccharide appearing in a sample. Provided are methods of measuring the concentration of a saccharide in a sample as well as methods of measuring the concentration of a halogenated saccharide in a sample. In certain aspects the sample is abiological sample and the methods further include correlating the measured concentration of saccharide in the biological sample to the gastrointestinal permeability in the individual. Disclosed are also kits for performing the above methods.Type: ApplicationFiled: February 12, 2019Publication date: November 25, 2021Inventors: Angel Resendez, Sanjay Malhotra
-
Publication number: 20200375977Abstract: Compounds, compositions and methods are provided for the inhibition of GBP1. The subject inhibitor compounds can act by inhibiting GBP1 alone and/or GBP1: pro-survival kinase (e.g. serine/threonine-protein kinase pim-1 (PIM1)) interactions. Aspects of the subject methods include contacting a cellular sample with a GBP 1 inhibitor to inhibit the GBP 1 alone and/or GBP 1: PIM 1 interactions. Also provided are compositions and methods for treating cancer. In certain cases the cancer is resistant towards chemotherapy and radiation therapy.Type: ApplicationFiled: March 12, 2019Publication date: December 3, 2020Inventors: Sanjay Malhotra, Vineet Kumar, Dhanir Tailor
-
Publication number: 20200345661Abstract: ?-NETA analogs are provided for the treatment of inflammatory disease.Type: ApplicationFiled: April 13, 2020Publication date: November 5, 2020Inventors: Sanjay Malhotra, Vineet Kumar, Melissa LaJevic, Mallesh Pandrala, Brian A. Zabel
-
Publication number: 20200101108Abstract: Provided herein are compositions and methods for preventing or reversing T cell exhaustion. In particular, the present invention relates to methods of preventing or reversing T cell exhaustion by exposing T cells experiencing T cell exhaustion to particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), or by expanding genetically engineered T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).Type: ApplicationFiled: March 30, 2018Publication date: April 2, 2020Inventors: Rachel LYNN, Crystal MACKALL, Evan WEBER, Sanjay MALHOTRA
-
Patent number: 7790689Abstract: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.Type: GrantFiled: May 30, 2007Date of Patent: September 7, 2010Assignee: Ranbaxy Laboratories LimitedInventors: Ashwani Kumar Verma, Sanjay Malhotra, Sankaranarayanan Dharmarajan, Abhijit Ray, Rajkumar Shirumalla
-
Patent number: 7674811Abstract: The present invention relates to 5-lipoxygenase inhibitors. Compounds disclosed herein can be useful in the treatment of bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, urticaria, atopic dermatitis, allergic rhinitis, other inflammatory, and autoimmune diseases. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as 5-lipoxygenase inhibitors are also provided.Type: GrantFiled: March 14, 2007Date of Patent: March 9, 2010Assignee: Ranbaxy Laboratories LimitedInventors: Ashwani Kumar Verma, Sanjay Malhotra, Abhijit Ray, Shirumalla Raj Kumar
-
Publication number: 20090131430Abstract: The present invention relates to novel azabicyclo derivatives as anti-inflammatory agents. The compounds provided herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as sepsis, rheumatoid arthritis, inflammatory bowel disease, type-1 diabetes, asthma, chronic obstructive pulmonary disorder, organ transplant rejection and psoriasis. Also provided herein are pharmacological compositions containing compounds provided herein and associated methods of treating sepsis, rheumatoid arthritis, inflammatory bowel disease, type-1 diabetes, asthma, chronic obstructive pulmonary disorder, organ transplant rejection and psoriasis, and other inflammatory and/or autoimmune disorders, using the compounds.Type: ApplicationFiled: November 23, 2005Publication date: May 21, 2009Inventors: Venkata P. Palle, Rakesh Kumar Singh, Sanjay Malhotra, Yogesh Bhaskarrao Waman, Ashwani Verma, Abhijit Ray, Geeta Sharma
-
Publication number: 20080300196Abstract: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory, cancer, cardiovascular and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, pruritis or allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, cancer, cardiovascular diseases, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, pruritis or allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.Type: ApplicationFiled: October 3, 2007Publication date: December 4, 2008Inventors: Ashwani Kumar Verma, Sanjay Malhotra, Sankaranarayanan Dharmarajan, Rajkumar Shirumalla, Abhijit Ray
-
Publication number: 20080114031Abstract: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.Type: ApplicationFiled: March 28, 2007Publication date: May 15, 2008Inventors: Viswajanani Sattigeri, Sudershan Arora, Mohammad Salman, Venkata Palle, Ashis Mukherji, Ashwani Verna, Sanjay Malhotra, Sankaranarayanan Dharmarajan, Abhijit Ray, Raj Shirumalla
-
Publication number: 20080021080Abstract: The present invention relates to 5-lipoxygenase inhibitors. Compounds disclosed herein can be useful in the treatment of bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, urticaria, atopic dermatitis, allergic rhinitis, other inflammatory and autoimmune diseases. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as 5-lipoxygenase inhibitors are also provided.Type: ApplicationFiled: March 14, 2007Publication date: January 24, 2008Inventors: Ashwani Verma, Sanjay Malhotra, Abhijit Ray, Shirumalla Kumar
-
Publication number: 20070287673Abstract: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.Type: ApplicationFiled: May 30, 2007Publication date: December 13, 2007Inventors: Ashwani Verma, Sanjay Malhotra, Sankaranarayanan Dharmarajan, Abhijit Ray, Rajkumar Shirumalla
-
Publication number: 20050261330Abstract: The present invention relates to derivatives of 2,2,4-trisubstituted tetrahydrofuran as potential antifungal agents. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing the fungal infections in mammals, preferably humans.Type: ApplicationFiled: April 12, 2002Publication date: November 24, 2005Inventors: Mohammad Salman, Ashwani Verma, Sanjay Malhotra, Ashok Rattan
-
Publication number: 20040249147Abstract: Methods for producing azole compounds useful as intermediates for antifungal compounds and compositions including reaction of epoxy alcohols with reactants having active hydrogen attached to nitrogen, oxygen or sulfur in the presence of redox coupling agents. In some embodiments, a procedure known as a Mitsunobu reaction is utilized for the transformations.Type: ApplicationFiled: July 2, 2004Publication date: December 9, 2004Inventors: Jitendra Sattigeri, Jasbir Singh Arora, Sanjay Malhotra, Ashwani Kumar Verma, Mohammad Salman